Voor zorgverleners

Publicaties op basis van Nederlandse RWE veiligheids- en effectiviteitsdata in de behandeling van atopisch eczeem

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results1

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

146 for Lipid Management After ACS

Dupixent® CRSwNP

2024 ESC Guidelines for the management of chronic coronary syndromes

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications. Caplacizumab is an innovative nanobody^® and cornerstone in the treatment of iTTP.¹ This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.²

Infographic: Impact of Type 1 Diabetes Diagnosis

This infographic summarizes survey data^* about the impact that families in the Netherlands and Belgium have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).

Detectability of Autoimmune Type 1 Diabetes

Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.^1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.²

Time to Rethink T1D?

Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.